The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin- converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising a chymase inhibitor, or c. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor and a pharmaceutical composition comprising a chymase inhibitor. The invention also relates to a method for decreasing the blood pressure in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject. In another aspect, the invention relates to a method for treating a disease related to the RAS in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject.La présente invention concerne une composition pharmaceutique comprenant a. au moins un inhibiteur de l'aspartyl aminopeptidase et au moins un inhibiteur de l'enzyme de conversion de l'angiotensine, ou b. au moins
